IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel secured up to $7M in equity investment from UroGen® to advance the Phase 2 study of TumoCure for advanced head and neck cancer. The deal also gives UroGen access to IntraGel’s biodegradable sustained-release gel platform, which the company says has broad potential across solid tumors. This funding supports clinical progress with a modest positive signal for prospects, though it does not yet change outcomes until Phase 2 results.

Analysis

IntraGel secured up to $7M in equity investment from UroGen® to advance the Phase 2 study of TumoCure for advanced head and neck cancer. The deal also gives UroGen access to IntraGel’s biodegradable sustained-release gel platform, which the company says has broad potential across solid tumors. This funding supports clinical progress with a modest positive signal for prospects, though it does not yet change outcomes until Phase 2 results.